



საქართველოს შრომის, ჯანმრთელობისა
და სოციალური დაცვის სამინისტრო
MINISTRY OF LABOUR, HEALTH AND SOCIAL
AFFAIRS OF GEORGIA



KA030124412470518

საქართველო, თბილისი 0119, აკ.წერეთლის გამზ.144; ტელ.: (+995 32) 251 00 11; ცხელი ხაზი: (+995 32) 251 00 26; 15 05; ელ.ფოსტა: info@moh.gov.ge
144 Ak.Tsereteli ave., 0119, Tbilisi, Georgia; Tel: (+995 32) 251 00 11; Hot line: (+995 32) 251 00 26; 15 05; E-mail: info@moh.gov.ge

№ 01/30843

25 / May / 2018

Mr. Christian Gruttke
Official in Charge
Embassy of the Federal Republic of Germany in Tbilisi

Dear Mr. Gruttke,

Subject: Reference to RK-10-516.80 E Fibrosarkom

Let me express the assurance of my highest respect and acknowledgments for continuous support, reliable partnership, and fruitful collaboration. Herewith, let me kindly provide you with the requested information within the competence of the Ministry of Labour, Health and Social Affairs of Georgia:

Treatment of oncology patients in Georgia (including outpatient care), in particular, hormonotherapy, chemotherapy, radiotherapy and all the research and medications related to these procedures are provided under the Universal Health Care (UHC) State Program, with appropriate co-financing, in accordance with the packages of the beneficiaries, within the existing limits.

However, it is worth mentioning that the cost of medications - Pazopanib and Trapidine are not covered under the above mentioned state program.

In addition, the treatment of fibrosarcoma (any localization) is carried out in Georgia with relevant guidelines and protocols, in compliance with the modern standards, necessary for the prevention and treatment of the disease (please, find the attached annex - treatment methods for the above mentioned diagnosis, provided by the relevant field expert of the Ministry).

Furthermore, in Georgia palliative outpatient (terminal stage) and inpatient care is provided by the relevant co-payment.

As for the medicines mentioned in the letter, we would like to inform you that almost all kind of medicines used by international guidelines for oncological diseases are registered in Georgia, including "Votrient" (Pazopanib-Manufacturer Glaxo Wellcome S.A. Spain) and Pazopanib. "Trabectedin" is not registered in Georgia, though in accordance with the Georgian legislation, after submitting the relevant documentation to the LEPL State Regulation Agency for Medical Activities by the patient, individual drug purchase (registration) can be performed.

In addition, financing of services that are not covered by the State Program could be considered by the "Referral Service Commission" under the Ministry of Labour, Health and Social Affairs of Georgia after receiving necessary documentation from the patient/service provider.

Sincerely yours,

Head of HR Management and International Relations
Department

Sofiko Belkania

